Multiple myeloma is a blood cancer of plasma cells, the antibody-producing cells in the bone marrow. Many of the newest myeloma drugs are antibodies, bispecific T-cell engagers, or CAR-T cell therapies, so this tag covers the narrower set of stories where peptides play a part.
The main peptide drug in the field is Oncopeptides' Pepaxti (melflufen), a peptide-drug conjugate given with dexamethasone. In the European Union it is authorized for patients who have had at least three prior lines of therapy and whose disease is triple-class refractory, and on September 17, 2026 the CHMP recommended extending it to third-line patients whose disease is refractory to lenalidomide. The FDA withdrew the drug's U.S. approval, under the name Pepaxto, on February 23, 2024.
See #oncopeptides, #melflufen, and #peptide-drug-conjugate.
Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.
TJ Biopharma and Biogen said China's National Medical Products Administration approved felzartamab for injection, branded Jingfei, on Thursday, August 13, 2026 for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. It is the anti-CD38 antibody's first approval anywhere; TJ Biopharma submitted the application in December 2024. In April 2026 Biogen agreed to pay $100 million upfront and up to $750 million in milestones for TJ Biopharma's Greater China rights, giving Biogen worldwide rights; Biogen handles commercialization in the region, and TJ Biopharma manufactures the drug at its Hangzhou facility. Outside China, Biogen is testing felzartamab in Phase 3 trials in antibody-mediated rejection after kidney transplant, IgA nephropathy, and primary membranous nephropathy.
Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.
Oncopeptides AB (Nasdaq Stockholm: ONCO) will present preclinical data on its SPiKE platform at AACR 2026, showing synergistic effects when combining an affibody-derived bispecific engager with expanded adaptive NK cells (ADAPT-NK) in a humanized multiple myeloma mouse model. The approach leverages peptide-scaffold targeting to direct NK-cell cytotoxicity at malignant plasma cells in difficult-to-treat cancers.